Delta, Kelowna, BC - October 1, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 475 (TSX: WEED) (NYSE: CGC) (CSE: ACRG.A.U) (TSX: TGOD) (CSE: HAVN)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today's podcast we look at a few public and private company announcements.
Canopy Growth Corporation (TSX:WEED) (NYSE:CGC) and Acreage Holdings, Inc. (CSE:ACRG.A.U) (OTC: ACRHF) announced today that following the implementation of their amended arrangement, Acreage has developed a plan to market Canopy Growth's diverse beverage portfolio in the United States.
Leading with legal adult-use markets in Illinois and California, Acreage anticipates launching Canopy Growth's select, sessionable THC beverage formulations in summer 2021. In addition to selling products in its own dispensaries, Acreage will access existing distribution channels through strategic corporate relationships.
"We have had an incredibly successful introduction into the Canadian cannabis-infused beverage industry with over 1.7 million cans of our THC-infused RTD beverages, like Tweed's Houndstooth & Soda and Bakerstreet & Ginger sold to date," shared Canopy Growth CEO, David Klein. "We introduced a new product category to cannabis consumers that we knew had the potential to disrupt one of the most mature industries and since launching in Canada, Canopy Growth now owns 5 of the top 6 SKUs in the beverage category with a 74% market share. We are excited for Canopy's beverages to be introduced to the U.S. market next summer."
"We see THC-infused beverages as a game-changer in U.S. cannabis, and we are excited to launch Canopy Growth's unique beverage offerings to our core markets offering the greatest growth potential next year," said Bill Van Faasen, Interim CEO of Acreage Holdings. "We are already working on our beverage production capabilities, and look forward to tapping the wealth of experience and research Canopy can offer following its successful entry in the category last year."
The Companies look forward to bringing a sessionable infused beverage offering to U.S. consumers that will more closely liken itself to current beverage-alcohol serving sizes.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF), a leading producer of premium certified organically grown cannabis, announced that it has received import licences from the Australian and German authorities, and has applied for export licences with Health Canada.
These licences enable TGOD to export its premium certified organically grown products for validation. The Company anticipates validation will be completed by the end of the year and is on track to commence commercial export of medical cannabis products in 2021.
"TGOD was the first certified organic Canadian licensed producer to be granted an EU-GMP certificate. Today we are one step closer to fulfilling our vision of becoming the leading organic cannabis brand globally," commented Brian Athaide, CEO of TGOD. "Obtaining import licences from Australia and Germany is testament to the robust quality assurance system we have implemented across our operations and supply chain. We look forward to providing access to our high-quality products to Australian and German patients," added Athaide.
TGOD signed a distribution agreement with Australia's LeafCann and has access to a vast network in Europe through its wholly owned subsidiary, TGOD Europe. The Company expects to complete its first commercial shipment in 2021.
LYTE Clinics announced joining the University Health Network and Medical Cannabis by Shoppers in a first-of-its-kind Real World Evidence study with medical cannabis.
The Medical Cannabis Real-World Evidence (MC-RWE) clinical trial will allow patients to select medical cannabis products that are tested, from seed straight through to packaging. Patients using the online portal created by Medical Cannabis by Shoppers, will know exactly what is in their product: how many milligrams of THC and cannabidiol are being consumed, and if it works for them, they can rely on the product being exactly the same, from batch to batch. Patients in the MC-RWE clinical trial will have access to a wide range of products including dried flower, oil extracts, edibles, and topical preparations through the portal, which is the online platform for the sale of medical cannabis by Canadian retail pharmacy chain, Shoppers Drug Mart.
LYTE Clinics' practitioners will assist patients in enrolling in the study, as well as offering support and medical advice to participants so that they can select the best products for their medical cannabis therapy.
LYTE is unique amongst cannabis clinics as the process of scheduling an appointment with a doctor, registering with a medical provider, and placing an order is all done online in a matter of minutes, using state-of-art telehealth software, with the benefit of minimizing wait time.
"LYTE's robust telemedicine platform will connect Canada's largest pharmacy network, Shoppers Drug Mart, with Canada's largest and most prestigious research institution, University Health Network, to enable this groundbreaking clinical study in medical cannabis." States Dr Dean Elterman, of University Health Network.
"Patients and practitioners need rigorously tested, genetically verified, fully tracked medical cannabis options, noted Ali Mohamed, President & CEO of Lyte Clinics. "The information gathered in the Medical Cannabis Real-World Evidence Study is critical to helping new patients find the type of cannabis that is proven to be best for their symptoms, which will lead to a better quality of life for thousands of Canadians."
Havn Life Sciences Inc. (CSE:HAVN), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, announced that it has joined the Drug Science Medical Psychedelics Working Group consortium.
The working group was launched by Drug Science, the UK's leading independent scientific body on drugs that provides an evidence base that is free from political or commercial influence, which creates a foundation for sensible and effective drug laws by delivering, reviewing, and investigating scientific evidence relating to psychoactive drugs.
"Havn Life is thrilled to be supporting Drug Science's research on psychedelics," said Dr. Ivan Casselman (Ph.D., FLS), Havn Life's Chief Psychedelic Officer. "We are committed to advancing research in psychedelics, as well as collaborating with organizations and academic institutions around the world to tap into world-class, quality research. The development of sensible drug policy reform is a mission that both the working groups and Havn Life are highly aligned with."
Once again, today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android
Buy a cannabis guest post on Investorideas.com